Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: No present guidelines exist regarding the inclusion of atherogenic cancer or chemotherapy into atherosclerotic cardiovascular disease (ASCVD) screening or imaging screening guidelines. Individual physician preference often determines screening, and this is typically symptom guided.
Case Summary: A 30-year-old woman with early-stage breast cancer received atherogenic chemotherapy, with no prior atherogenic risk factors. She presented with angina and dyspnea on exertion 3 years after her last round of chemotherapy. An ischemic work-up was performed, and the patient was found to have premature critical stenosis in her proximal left anterior descending artery.
Discussion: Because more patients are living with cancer and survivors of atherogenic chemotherapy emerge, it is becoming more critical to improve ASCVD screening modalities.
Take-home Message: Expert consensus for patients with early-stage cancer treated with atherogenic chemotherapy should derive either their unique ASCVD algorithm, be included into pre-existing algorithms, or have their own multimodal imaging pathway.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaccas.2025.105001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Adipose tissue gene expression and longitudinal clinical phenotypes are early biomarkers of lipid-regulating drug usage.
Sci Rep
August 2025
Department of Twin Research & Genetic Epidemiology, King's College London, London, UK.
Cardiovascular disease progression is characterised by the dysregulation of lipid metabolism and pro-atherogenic effects of adipose tissue signalling. Recent findings from the analysis of transcriptomic data in bulk tissue has enabled these insights and revealed important changes in gene expression. However, few studies have explored these molecular mechanisms before the onset of cardiovascular disease.
View Article and Find Full Text PDFLong-term cardiometabolic and bone health consequences of ketogenic diet in children with refractory epilepsy.
Ital J Pediatr
August 2025
Department of Pediatrics, Faculty of Medicine, Menoufia University, Yassin Abdel-Ghafar Street, Shebin El-Kom, Menoufia, 32511, Egypt.
Background: Ketogenic diet (KD) is a well-tolerated and efficacious therapy for refractory epilepsy (RE). While numerous mild short-term side effects have been reported, long-term cardiometabolic and bone heath consequences of KD need more advanced work-up and were not fully evaluated especially in children. So, we aimed to evaluate cardiac, vascular, metabolic, bone health and growth consequences in children with RE receiving KD for more than 2 years compared to those receiving antiepileptic drugs (AEDs ) without any dietary interference.
View Article and Find Full Text PDFImpact of Anabolic-Androgenic Steroids on Coronary Artery Disease: Insights From Optical Coherence Tomography.
JACC Case Rep
August 2025
Cardiology Department, Mouwasat Hospital Dammam, Dammam, Saudi Arabia.
Introduction: Anabolic-androgenic steroids (AAS), synthetic derivatives of testosterone, are misused by athletes to enhance performance despite known cardiovascular risks including dyslipidemia, hypertension, and acute myocardial infarction.
Case Summary: A 30-year-old male with a history of AAS abuse presented with acute chest pain and was diagnosed with non-ST elevation myocardial infarction. Coronary angiography revealed intimal hyperplasia, plaque erosion, and thrombus formation in the proximal left anterior descending artery, confirmed by optical coherence tomography.
Accelerated Atherosclerosis in Early-Stage Breast Cancer Following Chemotherapy.
JACC Case Rep
August 2025
Department of Cardiovascular Medicine, McLaren Flint, Flint, Michigan, USA; (b)Department of Interventional Cardiology, McLaren Flint, Flint, Michigan, USA; Department of Interventional Cardiology, McLaren Flint, Flint, Michigan, USA.
Background: No present guidelines exist regarding the inclusion of atherogenic cancer or chemotherapy into atherosclerotic cardiovascular disease (ASCVD) screening or imaging screening guidelines. Individual physician preference often determines screening, and this is typically symptom guided.
Case Summary: A 30-year-old woman with early-stage breast cancer received atherogenic chemotherapy, with no prior atherogenic risk factors.
Metformin suppresses atherosclerosis by dampening extramedullary myelopoiesis.
Am J Physiol Endocrinol Metab
September 2025
Diabetes and Metabolic Disease, St. Vincent's Institute of Medical Research, Melbourne, Victoria, Australia.
Impaired cholesterol homeostasis is a major factor contributing to the development and progression of atherosclerosis. Previous studies have shown that metformin, the first-line antidiabetic therapy, has cardioprotective effects in patients with diabetes. However, the antiatherogenic effect of metformin in nondiabetic individuals remains unclear.
View Article and Find Full Text PDF